Lomitapide: Targeting METTL3 to Overcome Osimertinib Resistance in NSCLC Through Autophagy Activation
ABSTRACT Osimertinib resistance remains a significant challenge in the treatment of non‐small cell lung cancer (NSCLC). N6‐methyladenosine (m6A) modifications are closely linked to various mechanisms of anticancer resistance and autophagy, offering new avenues for targeted therapies. However, the ro...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wiley
2025-03-01
|
| Colección: | MedComm – Oncology |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1002/mog2.70011 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|